-
公开(公告)号:US20230147455A1
公开(公告)日:2023-05-11
申请号:US17917175
申请日:2021-04-06
IPC分类号: A61K31/593 , A61K31/675 , A61P11/00
CPC分类号: A61K31/593 , A61K31/675 , A61P11/00
摘要: The invention relates to calcifediol for the prophylaxis and/or treatment of acute respiratory distress syndrome.
-
公开(公告)号:US20230140290A1
公开(公告)日:2023-05-04
申请号:US17795223
申请日:2021-01-26
申请人: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SY , UNIVERSITY OF SEVILLE , SERVICIO ANDALUZ DE SALUD
发明人: Jia ZHOU , Jimin XU , Javier SANCHEZ-CESPEDES , Judith BERASTEGUI-CABRERA , Maria Eugenia PACHON-IBANEZ , Jeronimo PACHON-DIAZ
IPC分类号: C07F9/6561 , C07F9/6512 , C07C233/81 , C07D307/85 , C07C233/76 , C07C225/22
摘要: Certain embodiments describe antiviral compounds and related methods of using such compounds.
-
公开(公告)号:US11565019B2
公开(公告)日:2023-01-31
申请号:US17045661
申请日:2019-04-08
发明人: Rafael Campos Cuerva , Beatriz Fernandez Muñoz , Miguel Angel Gómez Bravo , Carmen Cepeda Franco , Jordi Muntane Relat
摘要: The present invention provides for nanostructured fibrin and agarose hydrogels, preferably type VII agarose hydrogels, (NFAH) or non-nanostructured or pre-nanostructured fibrin and agarose hydrogels, preferably type VII agarose hydrogels, (FAH), as hemostatic agents designed for use as an adjunct or primary treatment in moderate intraoperative hemorrhage and in trauma. These hydrogels can be applied topically to the wound either on the skin in a laparotomy or as non-invasive manner in surgical procedures. Its nanostructure technology generates an adhesive stable fibrin clot required for hemostasis. The attachment properties of the hydrogel, as well as the rapid formation of a fibrin clot, ensures that a strong stable fibrin clot is formed shortly after application.
-
公开(公告)号:US11344531B2
公开(公告)日:2022-05-31
申请号:US15129327
申请日:2015-03-27
发明人: Darío Acuña Castroviejo , Germaine Escames Rosa , Pablo Bueno Laraño , Alfonso Mansilla Roselló , José Antonio Ferrón Orihuela , José Jorge Hernández Magdalena , Miguel Ángel Calleja Hernández , Desirée González Callejas , Ana Comino Pardo , Carmen Olmedo Martín , Carmen Venegas Maldonado
IPC分类号: A61K31/4045 , A61K47/10 , A61K9/00 , A61K9/19 , A61K45/06
摘要: The invention relates to an aqueous melatonin composition exhibiting surprising long-term stability and allowing high concentrations of said water-insoluble active ingredient. The properties of said composition render it useful as an injectable, for example, for the intravenous administration thereof.
-
公开(公告)号:US20210164053A1
公开(公告)日:2021-06-03
申请号:US16630021
申请日:2018-07-13
申请人: FUNDACIÓN DE INVESTIGACIÓN HOSPITAL 12 DE OCTUBRE , SERVICIO ANDALUZ DE SALUD , CONSE-JO SUPERIOR DE INVESTIGACIONES CIENTÍFI-CAS (CSIC)
发明人: Luis PAZ-ARES RODRÍGUEZ , Álvaro QUINTANAL VILLALONGA , Irene FERRER SÁNCHEZ , Sonia MOLINA PiNELO , Amancio CARNERO MOYA
IPC分类号: C12Q1/6886 , G01N33/574
摘要: The present invention describes a method for predicting the response of a subject suffering from lung cancer to treatment with FGFR inhibitors. The relationship between the expression of the biomarkers and the treatment response allows the subjects to be classified as responsive or unresponsive to the treatment, which facilitates the therapeutic decision-making of the attending clinician. The present invention also describes the biomarkers N-cadherin, FGFR1 and FGFR4, how to analyse them and how to interpret the results obtained, in order to administer FGFR inhibitors only to the subjects that are responsive to the treatment, thereby optimising the same, which allows the unresponsive subjects to be treated with alternative therapies to the FGFR inhibitors.
-
公开(公告)号:US10393758B2
公开(公告)日:2019-08-27
申请号:US14443814
申请日:2013-11-22
申请人: SERVICIO ANDALUZ DE SALUD , FUNDACIÓN PÚBLICA ANDALUZA PARA LA INVESTIGACIÓN DE MÁLAGA EN BIOMEDICINA Y SALUD (FIMABIS) , UNIVERSIDAD DE MÁLAGA
发明人: Óscar Fernández Fernández , Begoña Oliver Martos , Teresa Órpez Zafra , José Pavía Molina , Cristobalina Mayorga Mayorga , Laura Leyva Fernández , María Jesús Pinto Medel , Margarita Suardíaz García
IPC分类号: C07K14/565 , C07K14/705 , A61K38/04 , G01N33/68 , C07K14/715 , G01N33/564 , C07K16/28 , A61K38/00
摘要: The invention relates to a recombinant protein and uses thereof in the diagnosis and treatment of multiple sclerosis. The invention also relates to the recombinant protein IFNAR2.3, antibodies, compositions comprising same, and uses thereof. Among the uses thereof, the invention especially relates to a method for the diagnosis of multiple sclerosis, and to the diagnosis kit. The invention further relates to the use of the protein IFNAR2.3 in the preparation of a medicament for the treatment of multiple sclerosis.
-
7.
公开(公告)号:US20170360382A1
公开(公告)日:2017-12-21
申请号:US15624074
申请日:2015-12-14
摘要: The invention relates to a method for obtaining useful data about the angiogenesis in a patient's lower limbs, and particularly in the lower limbs of patients with diabetes subjected to treatment.
-
公开(公告)号:US20170321261A1
公开(公告)日:2017-11-09
申请号:US15512449
申请日:2015-09-18
发明人: María José SERRANO FERNÁNDEZ , Juan José DÍAZ MOCHÓN , Francisco GABRIEL ORTEGA , José Antonio LORENTE ACOSTA , José Luis GARCÍA PUCHE , Maria Paz RUIZ BLAS , Rosario María SÁNCHEZ MARTÍN
IPC分类号: C12Q1/68 , G01N33/574
CPC分类号: C12Q1/6841 , C12Q1/6804 , C12Q1/6886 , C12Q2537/16 , C12Q2600/158 , C12Q2600/178 , G01N33/574
摘要: The present invention provides an in vitro method of detecting circulating tumour cells, circulating tumour cells of epithelial phenotype and circulating tumour cells of epithelial to mesenchymal transition (EMTs), in a biological sample using, as an indicator, expression levels of miRNA-21, and obtaining a result of the method by comparing the expression levels of said miRNA-21 with a negative control or with a positive control, wherein if the expression levels in the cells of the biological sample are over-expressed in comparison to a negative control is indicative of the presence of circulating tumour cells in said biological sample or wherein if the expression levels in the cells of the biological sample are expressed in an amount greater than ⅔ of the maximum expression achieved in a positive control is indicative of the presence of circulating tumour cells in said biological sample.
-
9.
公开(公告)号:US20170226472A1
公开(公告)日:2017-08-10
申请号:US15501718
申请日:2015-08-04
发明人: Juan Antonio Marchal Corrales , Gema Jiménez González , Cynthia Morata Tarifa , María Ángel García Chaves , Macarena Perán Quesada
CPC分类号: C12N5/0037 , C12N5/0695 , C12N2500/90 , C12N2501/10 , C12N2501/11 , C12N2501/113 , C12N2501/12 , C12N2501/165 , C12N2501/22 , C12N2501/2306 , C12N2501/2308 , C12N2501/2312 , C12N2501/2323 , C12N2501/33 , C12N2501/39 , C12N2501/91 , C12N2501/999 , C12N2509/00
摘要: The present invention relates to a serum-free conditioned medium that solves the drawbacks mentioned in the prior art, as it does not require prior handling of the cells, and it furthermore allows starting from a large population with no additional cost. This medium favors in vitro proliferation and conservation of the pluripotency potential that allows maintaining a state that is undifferentiated with respect to the subpopulation of cancer stem cells (CSCs) and in turn does not allow survival of the differentiated cells.
-
10.
公开(公告)号:US20170183734A1
公开(公告)日:2017-06-29
申请号:US15312903
申请日:2015-05-22
申请人: SERVICIO ANDALUZ DE SALUD , UNIVERSIDAD DE CÓRDOBA , FUNDACIÓN PARA LA INVESTIGACIÓN BIOMÉDICA DE CÓRDOBA
发明人: Rosario López-Pedrera , Carlos Pérez-Sánchez , Carmen Castro Villegas , Patricia Limón-Ruiz , Yolanda Jiménez Gómez , Eduardo Collantes Estévez , Nuria Barbarroja Puerto
IPC分类号: C12Q1/68
CPC分类号: C12Q1/6883 , C12Q2600/106 , C12Q2600/158 , C12Q2600/178
摘要: The present invention relates to a method of predicting response of a human subject to anti-TNFa therapy, and preferably wherein the subject is suffering from rheumatoid arthritis.
-
-
-
-
-
-
-
-
-